» Articles » PMID: 21965223

Pulmonary Embolism: CT Signs and Cardiac Biomarkers for Predicting Right Ventricular Dysfunction

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2011 Oct 4
PMID 21965223
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to prospectively evaluate the accuracy of quantitative cardiac computed tomography (CT) parameters and two cardiac biomarkers (N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and troponin I), alone and in combination, for predicting right ventricular dysfunction (RVD) in patients with acute pulmonary embolism. 557 consecutive patients with suspected pulmonary embolism underwent pulmonary CT angiography. Patients with pulmonary embolism also underwent echocardiography and NT-pro-BNP/troponin I serum level measurements. Three different CT measurements were obtained (right ventricular (RV)/left ventricular (LV)(axial), RV/LV(4-CH) and RV/LV(volume)). CT measurements and NT-pro-BNP/troponin I serum levels were correlated with RVD at echocardiography. 77 patients with RVD showed significantly higher RV/LV ratios and NT-pro-BNP/troponin I levels compared to those without RVD (RV/LV(axial) 1.68 ± 0.84 versus 1.00 ± 0.21; RV/LV(4-CH) 1.52 ± 0.45 versus 1.01 ± 0.21; RV/LV(volume) 1.97 ± 0.53 versus 1.07 ± 0.52; serum NT-pro-BNP 6,372 ± 2,319 versus 1,032 ± 1,559 ng · L(-1); troponin I 0.18 ± 0.41 versus 0.06 ± 0.18 g · L(-1)). The area under the curve for the detection of RVD of RV/LV(axial), RV/LV(4-CH), RV/LV(volume), NT-pro-BNP and troponin I were 0.84, 0.87, 0.93, 0.83 and 0.70 respectively. The combination of biomarkers and RV/LV(volume) increased the AUC to 0.95 (RV/LV(volume) with NT-pro-BNP) and 0.93 (RV/LV(volume) with troponin I). RV/LV(volume) is the most accurate CT parameter for identifying patients with RVD. A combination of RV/LV(volume) with NT-pro-BNP or troponin I measurements improves the diagnostic accuracy of either test alone.

Citing Articles

Complications of Pulmonary Embolism in a Pediatric Patient.

Patil S, Zia A, Fuller J, Billa R, Goss K, Andersen N JACC Case Rep. 2025; 30(3):103221.

PMID: 39963205 PMC: 11830248. DOI: 10.1016/j.jaccas.2024.103221.


Impact of Natriuretic Peptide on the Evolution of Patients With Pulmonary Embolism and Neoplasm.

Nemtut D, Ulmeanu R, Nemeth N, Tudoran C, Motofelea A, Voita-Mekeres F Cureus. 2024; 16(11):e73853.

PMID: 39583604 PMC: 11585071. DOI: 10.7759/cureus.73853.


Ventricular volume asymmetry as a novel imaging biomarker for disease discrimination and outcome prediction.

McCracken C, Szabo L, Abdulelah Z, Condurache D, Vago H, Nichols T Eur Heart J Open. 2024; 4(4):oeae059.

PMID: 39119202 PMC: 11306927. DOI: 10.1093/ehjopen/oeae059.


Life expectancy in cancer patients with pulmonary thromboembolism: From clinical prognostic biomarkers and paraclinical investigations to therapeutic approaches (Review).

Nemtut D, Petreanu C, Ulmeanu R, Rajnoveanu A, Rajnoveanu R Exp Ther Med. 2024; 28(3):354.

PMID: 39071911 PMC: 11273361. DOI: 10.3892/etm.2024.12643.


Diagnosis of Pulmonary Embolism: A Review of Evidence-Based Approaches.

Thomas S, Weinberg I, Schainfeld R, Rosenfield K, Parmar G J Clin Med. 2024; 13(13).

PMID: 38999289 PMC: 11242034. DOI: 10.3390/jcm13133722.